Skip to content

Pioneering Staffs Blood Screening Business Sold To Europe

Sanguin Group, which has its headquarters in Barton-under-Needwood, has been sold to German firm STRATEC Biomedical Systems AG for an undisclosed sum. The deal was led by the Birmingham office of Kroll Corporate Finance.

The Staffordshire based company, which has developed into the world’s leading supplier of blood processing software with an extensive worldwide customer base, has been sold by its founder.

Sanguin was founded in 1983 by current chairman and main shareholder David Vale, and its first product was a data management system for hospital blood banks. Rick Whelan, shareholder and co-director joined Sanguin in 1988 and has been key in developing the business to its current status.

During the past 23 years, the company has developed its software products and is now recognised as the world leader in the field of blood transfusion donation processing.

In addition to its UK business, it has a US operation, Sanguin International Inc, which was formed in 1992.

New owner STRATEC was founded in 1979 and is today a world-class development and manufacturing house providing its instruments and services to the leading in-vitro diagnostic companies. The company’s head office is in Birkenfeld, Germany. STRATEC is listed in the prime standard on the German stock exchange.

Shah Zaki, director of Kroll’s mergers and acquisition team in Birmingham, said that STRATEC’s purchase of Sanguin was a strategic move by the German company.

“Our previous business relations with STRATEC have been excellent, it was therefore a comfortable choice for us to become part of the STRATEC organisation. The natural synergy between our products is going to make us a very significant player in future business with our well established customer base and provide an excellent platform for future opportunities.”
David Vale, Chairman and Shareholder

“STRATEC is a developer and manufacturer of the equipment used in the field of diagnostics and life sciences, and Sanguin is a provider of software for the same sector, so together they are a good fit. Sanguin’s future plans are to increase their market presence by integrating their software into the ever increasing complex instrumentation required for safe and effective blood screening. In addition this strategic move will provide further opportunities in the clinical market and fits in well with STRATEC´s business strategy.”
Shah Zaki, Director at Kroll Corporate Finance

“Under the terms of the deal, Sanguin’s shareholders, David Vale and Rick Whelan, will remain in charge of the company for the foreseeable future.”
Duncan Macrae, Investment Manager of Dunedin

Similar news

All news